This article is more than 5 years old. Information may no longer be current.

Pfizer first quarter revenue up almost 50% over last year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Pfizer reported first quarter revenues of $12.49 billion, an increase of 47% from the same period 1 year ago. The company attributed the substantial increase to the inclusion of Pharmacia’s products after the acquisition of that company last April.

Pfizer’s human pharmaceutical operations generated revenues of $11 billion, of which the consumer health care business generated $804 million, according to a press release from the company. Overall net income for Pfizer was $2.33 billion for the quarter.

“Four of the world’s 11 best-selling medicines are marketed by Pfizer, and 14 of our medicines lead their therapeutic areas,” said Karen Katen, executive vice president of the company and president of Pfizer Global Pharmaceuticals.

“Pfizer is aggressively rounding out its portfolio of blockbusters with specialty products focused on meeting urgent medical needs, such as in oncology and ophthalmology,” she added.

Within ophthalmology, Xalatan/Xalcom (latanoprost) is the company’s leading drug, with worldwide first quarter revenues of $279 million, $180 million of which was generated outside the United States.